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double XY probe, in sex-mismatched pairs, and VNTR, using PCR
with Apo-B, D1S80, vWF and DXS52 primers in all patients.
Mucositis and acute GVHD were more evident in the Bu group.
Late rejection occurred specially in the ATG group. All the others
variables and overall survival were similar between these two con-
ditionings. By FISH evaluation, there were complete chimerism in
8 of 10 patients and there was a case of mixed chimera and another
of autologous reconstitution. VNTR determined chimera in 15 of
17 donor/ recipient pairs (88.2%). Complete chimerism, analyzed
by all primers were seen in 8 of 17 (47%) patients. Mixed chimer-
ism and autologous reconstitution patients, observed by FISH,
were conﬁrmed by VNTR just using D1S80 and vWF primers,
respectively. We conclude that both conditioning regimens were
effective and the analyzed clinical data were comparable between
the groups, however, a larger number of patients need to be studied
in order to establish the best conditioning. The methods for eval-
uation of the chimera are sensitive and informative using VNTR
and FISH methodologies.
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EARLY EXPANSION OF LYMPHOID CELLS PRECEDES MYELOID EN-
GRAFTMENT FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION
USING TRULY NONMYELOABLATIVE CYCLOPHOSPHAMIDE/FLUDARA-
BINE CONDITIONING
Pandurangadu, A.V.1, Menggang2, Nelson, R.P.3 1Indiana University
School of Medicine, Indianapolis, IN; 2Department of Medicine, Division
of Biostatistics, Indianapolis, IN; 3Department of Medicine, Division of
Hematology/Oncology and the Indiana University Cancer Center, Indi-
anapolis, IN.
Little is known regarding the mechanism of engraftment of
allogeneic cells in humans, partially because there are few cells to
analyze in the early (ﬁrst 2 weeks) post-transplant period. After
myeloablative conditioning, monocytes are the initial donor cells
identiﬁed in recipients’ blood, followed by polymorphonuclear
leukocytes and then lymphocytes.
Forty-nine consecutive patients with hematological malignancies
(median age, 55 years) received PBMCs from a matched related
(MRD) or unrelated (MUD) donor following cyclophosphamide,
60 mg/kg on days –6 and –7 (total dose 120 mg/kg) and ﬂudara-
bine, 25 mg/m2 for 5 consecutive days (day –5 through day –1; total
dose, 125 mg/m2). GVHD prophylaxis consisted of cyclosporine
(n33) or cyclosporine  mycophenolate mofetil (n16). Acyclo-
vir, ﬂuconazole and quinolone prophylaxis were provided and
freshly harvested, non-manipulated PBMCs were infused within 24
hours of collection. One patient with chronic lymphocytic leuke-
mia (CLL) and a pre-transplant lymphocyte count of 150,000/
mm3 (considered an outlier) was removed from the analysis. A
database (Excel®, MS, Redwood, CA) was utilized to record white
blood counts (WBC) obtained from the computerized medical
record; each patient’s total WBC, neutrophil, lymphocyte, and
monocyte percentages were recorded from day –7 to day 30.
Cumulative data were plotted using S-Plus® software (Insightful,
Seattle, WA) and median times to peak percentages were deter-
mined. Patients who received conventional conditioning and sim-
ilar grafts prior to transplantation for hematological malignancies
(AML or MDS) over a similar time period (n46) were studied and
engraftment patterns compared.
The following phenomena were observed after nonmyeloablative
transplantation: (1) no ¨ bump¨ , (increase in the peripheral WBC)
the day following cell infusion; (2) resolution of neutropenia at a
median of 12 days after MUD transplants and 15 days after MRD
transplants (p0.778); (3) median peak lymphocyte, monocyte and
polymorphonuclear percentages occurred 9, 12 and 23 days post-
infusion, respectively.
Early disappearance of infused cells from the circulation and
relative expansion of lymphocytes preceding the emergence of
monocytes and polymorphonuclear cells suggests that relatively
quick engagement of donor cells by the marrow microenvironment
is followed by an immunologically active process after truly non-
myeloablative cyclophosphamide/ﬂudarabine conditioning.
263
NON-MYELOABLATIVE CONDITIONING THERAPY WITH FLUDARABINE,
CYCLOPHOSPHAMIDE AND ATG ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION FROM HLA-IDENTICAL SIBLING DONOR IN
PATIENTS WITH SEVERE APLASIC ANEMIA (SAA)
Pawlowska, A.1, Bolotin, E.1, Falk, P.1, Forman, S.1, LaBossiere, D.1,
Rosenthal, J.1 1City of Hope National Medical and Research Center,
Duarte, CA.
Allogeneic bone marrow transplantation (BMT) from an HLA-
identical sibling is a curative form of therapy for patients with
acquired severe aplastic anemia.
Survival has signiﬁcantly improved over the past 3 decades. The
actuarial risk of rejection has been reduced to about 7%. Improved
results with survival in excess of 90% have been reported. Current
preparative therapies are associated with early and late sequelae
such as acute and chronic graft-versus-host disease (aGvHD or
chGvHD, respectively) and secondary tumors. In two patients (6
years and 11 years old) with SAA, who had an HLA-identical
sibling donor, but could not proceed with myeloablative therapy at
the time of transplant for various reasons (delay in results of
chromosome stability and fragility in one patient and abnormal
pulmonary function in the second), had a non-myeloablative pre-
parative regimen with Fludarabine (30 mg/m2x4 doses) Cyclophos-
phamide (5 mg/kgx4 doses) and rabbit ATG (1.5 mg/kgx4 doses)
followed by an unmanipulated allogeneic BMT. Graft versus host
disease prophylaxis consisted of Cyclosporine from day -1 and
Methotrexate 15 mg/m2 on day1 and 10 mg/m2 on days3,6,
11 after transplant. Myeloid engraftment occurred on day 15
and day 28. The time to a platelet count 20,000 unsupported
was 11 days and 29 days. No transplant-related toxicities,
including mucositis or alopecia, were recorded. There were no
signs for aGvHD or chGvHD. The patients continue with full
donor chimerism 31 months and 6 months post transplant, respec-
tively. This data suggests that a non-myeloablative, immunosup-
pressive regimen is sufﬁcient to provide a stable engraftment in
patients with SAA. This approach may be associated with de-
creased transplant-related short- and long-term toxicities. A larger
study is needed to fully evaluate the outcome and toxicities proﬁle
associated with this conditioning.
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INFLUENCE OF INTERLEUKIN-6 (IL-6) GENE POLYMORPHISM ON THE
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TRANSPLANTATION
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mato-Oncology Dpt., University Hospital, Olomouc, Czech Republic;
2Dpt. of Biophysics, Medical School of Palacky University, Olomouc,
Czech Republic.
BACKGROUND: IL-6 is an important mediator of inﬂamma-
tion and its production depends on the functional IL-6 gene
polymorphism (IL-6-174*G/C). Allele G expression is associated
with higher IL-6 production. The polymorphism of recipient
and/or donor might inﬂuence immunological reactions after allo-
geneic stem cell transplantation (SCT), particularly graft vs. host
disease (GvHD) and graft vs. tumor (GvT) one.
AIM OF STUDY: To assess the inﬂuence of recipient/donor
functional IL-6 gene polymorphism on the development of acute/
chronic GvHD, tumor relapse and mortality.
PATIENTS AND METHODS: 56 patients were allografted
from HLA-identical related donor. 54 recipients (96%) underwent
the procedure because of incurable hematological malignancy and
33 ones (59%) after reduced intensity conditioning (RIC). IL-6-
174* genotyping of recipients/donors was provided by the use of
polymerase chain reaction with sequential speciﬁc primers (PCR-
SSP). The inﬂuence of GvHD development, tumor relapse and
mortality on the IL-6-174*G/C allele manifestation in recipients/
donors was assessed by the methods of univariate as well as mul-
tivariate statistical analysis.
RESULTS: Statistical analysis did not conﬁrm the signiﬁcant
inﬂuence of functional IL-6 gene polymorphism of recipients/
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